Lillie James Woodruff: insider trades.
Lillie James Woodruff reported 9 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($951K), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 8
- Companies
- 1
- Name as filed
- Lillie James Woodruff
Companies
| Company | Relationship | Transactions |
|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | Officer · Chief Scientific Officer | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-17 | MapLight Therapeutics, Inc. | A | 7,730 | $0 | 210,110 | Form 4 |
| 2026-08-03 | MapLight Therapeutics, Inc. | S | 22,082 | $12.54 | 202,380 | Form 4 |
| 2026-07-17 | MapLight Therapeutics, Inc. | S | 2,077 | $37.9 | 224,462 | Form 4 |
| 2026-07-16 | MapLight Therapeutics, Inc. | S | 12 | $37.96 | 226,539 | Form 4 |
| 2026-07-16 | MapLight Therapeutics, Inc. | S | 3,526 | $37.26 | 226,551 | Form 4 |
| 2026-07-16 | MapLight Therapeutics, Inc. | S | 5,009 | $36.45 | 230,077 | Form 4 |
| 2026-07-15 | MapLight Therapeutics, Inc. | S | 5,393 | $36.99 | 235,098 | Form 4 |
| 2026-07-15 | MapLight Therapeutics, Inc. | S | 12 | $37.54 | 235,086 | Form 4 |
| 2026-07-15 | MapLight Therapeutics, Inc. | S | 2,238 | $36 | 240,491 | Form 4 |
Questions
What stock did Lillie James Woodruff buy or sell?
Lillie James Woodruff reported 9 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 8 sales ($951K), across 1 company.
Is Lillie James Woodruff the same person as other filers with this name?
This page covers SEC CIK 1728746 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/lillie-james-woodruff-1728746.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.